A method for synthesizing dissymmetric sulfoether includes the following step: a) under the condition of tetrabutylammonium halide catalysis, compounds having a structure of formula (I), compounds having a structure of formula (II) and salts having sulfur and oxygen are reacted in a solvent to give dissymmetric sulfoether having a structure of formula (III).

A method for synthesizing dissymmetric sulfoether includes the following step: a) under the condition of tetrabutylammonium halide catalysis, compounds having a structure of formula (I), compounds having a structure of formula (II) and salts having sulfur and oxygen are reacted in a solvent to give dissymmetric sulfoether having a structure of formula (III).

A method for synthesizing dissymmetric sulfoether includes the following step: a) under the condition of tetrabutylammonium halide catalysis, compounds having a structure of formula (I), compounds having a structure of formula (II) and salts having sulfur and oxygen are reacted in a solvent to give dissymmetric sulfoether having a structure of formula (III).

A method for synthesizing dissymmetric sulfoether includes the following step: a) under the condition of tetrabutylammonium halide catalysis, compounds having a structure of formula (I), compounds having a structure of formula (II) and salts having sulfur and oxygen are reacted in a solvent to give dissymmetric sulfoether having a structure of formula (III).

The invention relates to chemically reactive and/or biologically active compounds, reagents and compositions thereof. More particularly, the invention provides novel reagents that are useful in chemical synthesis, functionalization, delivery, probing and/or analytical measurements of small molecule drugs, proteins, antibodies and other biomolecules. The invention provides novel biologically active agents useful as diagnostics or therapeutics, and related composition and methods of uses thereof.

The invention relates to chemically reactive and/or biologically active compounds, reagents and compositions thereof. More particularly, the invention provides novel reagents that are useful in chemical synthesis, functionalization, delivery, probing and/or analytical measurements of small molecule drugs, proteins, antibodies and other biomolecules. The invention provides novel biologically active agents useful as diagnostics or therapeutics, and related composition and methods of uses thereof.

Provided is a silver ink including, as a major component, a silver malonate precursor represented by Formula 1 or Formula 2.

Provided is a silver ink including, as a major component, a silver malonate precursor represented by Formula 1 or Formula 2.

This document discloses a novel class of compounds for inhibiting bacterial growth and treating bacterial infection. The compounds target a key step of the futalosine pathway and therefore are effective for the selective inhibition of certain bacterial species and genera with reduced side effect in comparison with conventional antibiotics.

The present disclosure relates to lipid compounds of the general formula (I): (I) wherein R.sub.1 is selected from a C.sub.10-C.sub.22 alkyl, a C.sub.10-C.sub.22 alkenyl having 1-6 double bonds, and a C.sub.10-C.sub.22 alkynyl having 1-6 triple bonds; R.sub.2 and R.sub.3 are the same or different substituents; Y is selected from sulphur, sulfoxide, and sulfone; and X represents a carboxylic acid or a derivative thereof, a carboxylic ester, a carboxylic anhydride or a carboxamide; or a pharmaceutically acceptable salt, complex or solvate thereof. The disclosure also relates to pharmaceutical compositions and lipid compositions comprising such compounds, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to the cardiovascular, metabolic and inflammatory disease area.